Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3][4][5][6] The drug is no longer under development.
Clinical data | |
---|---|
Other names | PD-0332334; PD-332,334 |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C9H19NO2 |
Molar mass | 173.256 g·mol−1 |
3D model (JSmol) |
|
| |
|
{{cite journal}}
: Cite journal requires |journal=
(help)
{{cite journal}}
: Cite journal requires |journal=
(help)
{{cite journal}}
: Cite journal requires |journal=
(help)
{{cite journal}}
: Cite journal requires |journal=
(help)